Plasma fractionation and protein therapy manufacturing at scale
Prothya processes ~3 million liters of plasma annually into clotting factors, immunoglobulins, and albumin for pharma partners. The tech stack—SAP, Siemens Step 7, Ignition SCADA, MES, Power BI—reflects a capital-intensive, regulated operation; the hiring profile (manufacturing and engineering dominance, quality specialists, leadership gaps in data) and active projects (IT/OT automation, utility validation, capacity increases) signal a manufacturing org modernizing its control systems and pushing volume while wrestling with GMP compliance, CSV (Computerized System Validation) rigor, and data quality across production.
Notable leadership hires: Project Lead Engineering, Quality Director
Prothya Biosolutions is a plasma-derived medicine manufacturer formed in 2021 from the integration of Plasma Industries Belgium (with roots in the Belgian Red Cross) and Sanquin Plasma Products. The company operates a collection and fractionation facility in Brussels, converting human plasma into therapeutic proteins for pharmaceutical partners across multiple countries. Annual throughput is approximately 3 million liters. The product portfolio covers stable plasma derivatives—clotting factors, immunoglobulins, albumin solutions—alongside emerging protein therapy research. Operations span Belgium, Netherlands, and Canada; the organization is structured around manufacturing, engineering, quality assurance, and supply chain functions.
Core stack includes SAP (ERP), Siemens Step 7 and TIA Portal (PLC/automation), Wonderware and Ignition (SCADA/HMI), MES, Power BI (analytics), and Minitab (quality). These tools manage plasma processing, fractionation, and regulatory compliance.
Neder-Over-Heembeek, Brussels, Belgium. Additional hiring footprint in Netherlands and Canada. Founded 2021; 1,001–5,000 employees.
Other companies in the same industry, closest in size